NCT04129320View on ClinicalTrials.gov

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2022

Conditions
Head and Neck CancerSquamous Cell Carcinoma of Head and Neck
Interventions
BIOLOGICAL

enoblituzumab

anti-B7-H3 antibody

BIOLOGICAL

MGA012

anti-PD-1 antibody

BIOLOGICAL

MGD013

PD-1 X LAG-3 bispecific DART protein

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY

NCT04129320 - Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter